Antiallodynic and antihyperalgesic activities of a novel, highly potent GABA transporter isoform 1 (GAT1) inhibitor in two mouse models of neuropathic pain

DOI: 10.5176/2345-783X_PHARMA16.11

Authors: Kinga Sałat, Adriana Rojek, Ewelina Wojcieszak, Robert Sałat, Adrian Podkowa, Felix Kern, Jörg Pabel, Klaus T. Wanner, Katarzyna Kulig

Abstract:

The aim of this research was to investigate antiallodynic and antihyperalgesic properties of a newly synthesized and more potent (5 nM) than tiagabine GAT1 inhibitor, named DDPM-2571, in two mouse models of neuropathic pain, i.e., a model of streptozotocin (STZ)-induced painful diabetic neuropathy, and chemotherapy-induced peripheral neuropathy caused by oxaliplatin. Preliminary safety pharmacology studies of DDPM-2571 in neuropathic animals were also conducted using locomotor activity, rotarod and passive avoidance tests.

Keywords: GABA transporter isoform 1 neuropathic pain safety pharmacology